Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
sickle cell anemia
Biotech
Pfizer axes 3 drugs but eyes extra $25B in 2030 via outside work
Albert Bourla said it's "not the time to disrupt the momentum of the company" as Pfizer eyes $25B in additional 2030 revenue via outside science.
Kyle LaHucik
Feb 8, 2022 12:13pm
Sanofi tears up Sangamo deal in pivot to off-the-shelf approach
Jan 6, 2022 8:30am
Fierce Biotech’s top 10 data readouts in 2022
Dec 20, 2021 3:00am
Garuda bags $72M to advance off-the-shelf stem cell transplants
Sep 23, 2021 8:00am
Vertex adds to CRISPR fever with $1.2B Arbor gene-editing pact
Aug 24, 2021 7:00am
Fulcrum sees 'proof of biology' in phase 1 sickle cell data
Aug 11, 2021 10:10am
